Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children

Bibliography

• Pawłowska M. HCV infection in children 20 years after HCV virus appearance. Gastroenterol Pol 2010;17(2):135–7
   Google Scholar
• Bortolotti F, Iorio R, Resti M, et al. Epidemiological profile of 806 Italian children with hepatitis c virus infection over 15-year period. J Hepatol 2007;46(5):783–90
   PubMed Web of Science ®Google Scholar
• Vogt M, Lang T, Frosner G. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341(12):866–70
   PubMed Web of Science ®Google Scholar
• Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012;54(6):838–55
   PubMed Web of Science ®Google Scholar
• Pawłowska M, Halota W. HBV and HCV infections in children. Med Sci Rev Hepatologia 2006;6:17–20
   Google Scholar
• Jonas M. Hepatitis C in children. Hepatology Rev 2004;1:32–8
   Google Scholar
• Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy. Findings in the Peds-C trial. Hepatology 2008;47(3):836–43
   PubMed Web of Science ®Google Scholar
• Yeung LTF, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat 2007;14:797–805
   PubMed Web of Science ®Google Scholar
• Lucey JM, Finnegan R, Goode M, et al. Spontaneous clearance of hepatitis C virus in Irish children. Is Il28-B a useful tool in predicting spontaneous clearance of HCV? J Hepat 2014;60:s506
   Google Scholar
• Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900–7
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–93
   PubMed Web of Science ®Google Scholar
• El Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014;60(5):1767–75
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology 2014;60:98–105
   PubMed Web of Science ®Google Scholar
• Pawłowska M, Pilarczyk M, Halota W. Virologic response to treatment with pegylated Interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010;16(12):CR616–21
   Google Scholar
• Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. Hepatology 2008;23:226–30
   Web of Science ®Google Scholar
• Rodrigue JR, Balisteri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers:quality of life, cognitive and emotional outcomes. J Pediatr Gastroenterol Nutr 2009;48:341–7
   PubMed Web of Science ®Google Scholar
• Rodrigue JR, Balistreri W, Barbara Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology 2011;53(5):1468–75
   PubMed Web of Science ®Google Scholar
• Sokal E, Burgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827–31
   PubMed Web of Science ®Google Scholar
• Kelly DA, Haber B, Gonzales-Peralta RP, et al. Durability of sustained response shown I paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. J Viral Hepat 2012;19:263–70
   PubMed Web of Science ®Google Scholar
• Porto AF, Tormey L, Lim JK. Management of chronic hepatitis C infection in children. Curr Opin Pediatr 2012;24:113–20
   PubMed Web of Science ®Google Scholar
• Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2011;52(2):233–7
   PubMed Web of Science ®Google Scholar
• Narkewicz MR, Rosenthal P, Schwarz KB, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010;51(2):183–6
   PubMed Web of Science ®Google Scholar
• Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013;56(7):961–7
   PubMed Web of Science ®Google Scholar
• Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) Trial. Hepatology 2012;56(2):523–31
   PubMed Web of Science ®Google Scholar
• Schwarz KB, Gonzales-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents chronic hepatitis C. Gastroenterology 2011;140(2):450–8
   PubMed Web of Science ®Google Scholar
• Pawlowska M, Pilarczyk M, Foksinska A, et al. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon 2011;11(12):968–74
   Web of Science ®Google Scholar
• Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012;18(2):99–104
   PubMed Web of Science ®Google Scholar
• Słuzewski W, Kowala-Piaskowska A, Wysocki J, et al. Treatment of chronic hepatitis C in children with pegylated interferon alfa-2a and ribavirin - a multi-center study. Acta Pol Pharm 2012;69(2):319–26
   PubMed Web of Science ®Google Scholar
• Domagalski K, Pawłowska M, Tretyn A, et al. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis 2013;32(6):745–54
   PubMed Web of Science ®Google Scholar
• Shaker OG, Nassar YH, Nour ZA, Razki M. Single nucleotide polymorphisms of IL-10 and IL- 28B as predictors to the response of interferon therapy in HCV genotype 4 infected children. J Pediatr Gastroenterol Nutr 2013;57(2):155–60
   PubMed Web of Science ®Google Scholar
• Pawłowska M, Halota W. Pegylated interferon alpha-2a and ribavirin in the treatment of children with chronic hepatitis C. Hepatol Int 2010;4(1):99311; 182
   Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207–17
   PubMed Web of Science ®Google Scholar
• Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014;30(3):217–22
   PubMed Web of Science ®Google Scholar